B · Normal
[Watson Bio: Subsidiary's new coronavirus mRNA vaccine approved for marketing] On September 10th, Watson Bio (300142.SZ) announced that the company's wholly-owned subsidiary Yuxi Watson received the "Drug Registration Certificate" for the "new coronavirus mRNA vaccine" approved and issued by the State Food and Drug Administration. This vaccine is a third-generation COVID-19 vaccine iteratively developed based on mRNA platform technology. The antigen sequence is designed based on the S protein of the OmicronJN.1 strain. It is used to prevent diseases caused by COVID-19 infection in people aged 18 years and above. The company does not expect the approval of the vaccine to have a significant impact on its 2026 results.
A-share announcement express 🕐 2026-09-10 19:50
#RNA #Virus #vaccine #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[China Plastics: The stock price rose significantly on the first day of listing 09-22 20:40 [2 consecutive trading days of Hua Media Holdings: On September 22, the controll 09-22 20:29 [Xianhe Environmental Protection: Subsidiary plans to purchase GPU server equipm 09-22 20:14 [Bezi Technology: Signed a 249 million yuan daily operating contract with Kweich 09-22 20:11 [2-connected board Aiai Precision: The company, the acquirer Shanghai Yusheng an 09-22 19:42 [Mengke Pharmaceutical: Shareholders Best Idea and JSR plan to reduce their hold 09-22 19:34

Comments

0/500
Captcha (click to refresh)
No comments yet